Research Report
The Cell & Gene Therapy Market Report (2024–2035)
CGT reached $10B in revenue across 30 approved products. What remains unsettled isn't efficacy — it's manufacturing scale, cost structure, and solid tumor biology.
What the Framework Reveals
A base-case market assessment built on structural constraints, not clinical potential
$10B
current CGT revenue across 30 approved products
$44–71B
base-case 2035 projection, against optimistic forecasts above $100B
3
structural constraints that set the real ceiling: manufacturing scale, cost, solid tumor biology
Cell and gene therapy reached ten billion dollars of revenue across thirty approved products. The clinical case is settled in hematologic malignancies and a set of rare genetic diseases. What remains unsettled is manufacturing scale, cost structure, and solid tumor biology — and those three, not efficacy, set the ceiling. This report assesses the market across technology, modality, commercial performance, supply chain, pipeline, and demand.
Source: Market Research Report · Jan 2026 (data through Q3 2025) · MKA-33-RR, Executive Summary